 The ability to obtain serial biopsies is dependent on the patients experience. To understand the clonal progression of cancer and validate predictive and prognostic markers of response, studies now target biopsies both at enrollment and at progression. As Investigators strive to achieve this, improving our understanding of the patients experience will help us identify factors that positively and negatively impact on patient participation and influence the probability of successfully obtaining sequential samples. 